ERBB2 and prostate cancer: Similar studies reported antitumor activity for α-TOS on different cancer cell lines, including prostate cancer [26], gastric cancer [27], pancreatic cancer [4], resistant mesothelioma [28], and HER2 overexpressing breast cancer cell line [29].